May 13, 2026 —
Dyno Therapeutics announced significant updates to two mission-driven initiatives: the expanded Dyno Frontiers Network and the second annual Genetic Agency Technology Conference (GATC) 2026. The updates were shared during Dyno’s Scientific Symposium at the 29th American Society of Gene & Cell Therapy Annual Meeting, reflecting the company’s broader commitment to helping genetic medicine developers move innovative therapies toward the clinic more efficiently.
The Dyno Frontiers Network has evolved from the original Dyno Frontiers Program, launched in May 2025 to provide therapeutic developers with access to Dyno’s AI-designed AAV capsid technology. The expanded network now functions as a curated ecosystem connecting developers with the delivery technology, manufacturing capabilities, development services, regulatory expertise, investment capital, and strategic support needed to advance genetic medicine programs.
The network is designed to support therapeutic developers working with advanced payloads, including base editors, prime editors, epigenetic editors, trans-splicing constructs, vectorized antibodies, and tissue-specific synthetic promoters. By connecting these innovators with partners across the development continuum, Dyno aims to reduce common barriers in AAV gene therapy development, including delivery optimization, manufacturability, preclinical execution, regulatory planning, and financing.
The current Dyno Frontiers Network includes 15 therapeutic developers, seven manufacturers, six service providers, and 15 investor partners. Notably, the network allows members to partner directly with one another without Dyno acting as an intermediary. This structure is intended to create both a competitive marketplace and a collaborative community, enabling developers to identify the right partners while accelerating progress toward clinical translation.
PackGene is included among the manufacturing partners in the network, alongside other providers. The inclusion of manufacturing partners highlights the growing importance of scalable AAV production, process development, and manufacturing readiness as next-generation genetic medicine programs move closer to clinical development.
Dyno also announced that GATC 2026 will take place on November 18, 2026, in San Francisco. The conference will bring together patients, AI pioneers, technologists, entrepreneurs, therapeutic developers, and advocacy leaders to address the scientific, technical, and translational challenges facing genetic medicine. Topics will include patient stories, AI-enabled sequence design, frontier genetic technologies, preclinical development, manufacturing, and regulatory pathways.
The speaker lineup includes individuals with personal connections to rare genetic diseases and genetic agency, including patient advocates, foundation leaders, caregivers, scientists, and entrepreneurs working to advance gene therapies and personalized genetic medicines. Their stories underscore the urgency behind genetic medicine development and the importance of coordinated ecosystems that connect technology, expertise, funding, and patient-driven momentum.
Together, the expanded Frontiers Network and GATC 2026 reflect a broader trend in the gene therapy field: successful translation increasingly depends not only on breakthrough capsid or payload technologies, but also on integrated partnerships across delivery, manufacturing, regulatory strategy, investment, and patient advocacy. By building both a partner network and a community platform, Dyno aims to help more genetic medicine programs move from concept toward clinical impact.
